Condition: Primary Immune Thrombocytopenia (ITP) · Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.
The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with primary immune thrombocytopenia (ITP). The main questions it aims to answer are: * Is PN20 safe in these patients? * Could these patients potentially benefit from PN20 treatment? Participants will * Receive one subcutaneous injection of PN20 according to weight; * Visit the clinic for assessment.
This description comes directly from the study's public registry record.
Jing Sun · 86-13983367811 · sunj@pegbiocq.com
Always discuss trial participation with your own doctor first.
| Affiliated Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Recruiting |
| The Second Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| Jining First People's Hospital | Jining, Shandong, China | Recruiting |
| Hematology Hospital of Chinese Academy of Medical Sciences | Tianjin, Tianjin Municipality, China | Recruiting |
| The Second Affiliated Hospital of Kunming Medical University | Kunming, Yunnan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06880081